EXEL

SEC source: 0000939767-20-000058 · wf-form4_158777524774901.xml · nonDerivative · entry 3

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 335,985

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-20-000058 · wf-form4_158777524774901.xml · nonDerivative · entry 2

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 507,121

F1 · kind: On April 23, 2020, the Reporting Person gifted 80,799 shares to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended

F3 · ownership.nature: Shares held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended.

SEC source: 0000939767-20-000058 · wf-form4_158777524774901.xml · nonDerivative · entry 1

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,985

F1 · kind: On April 23, 2020, the Reporting Person gifted 80,799 shares to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended

F2 · balance_after: Includes 85,985 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000057 · wf-form4_158777434060565.xml · derivative · entry 4

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 100,000 shares

Expires 2021-09-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing the right to purchase a total of 500,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.

SEC source: 0000939767-20-000057 · wf-form4_158777434060565.xml · nonDerivative · entry 2

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 325,122

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2019.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.05. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-20-000057 · wf-form4_158777434060565.xml · nonDerivative · entry 1

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 425,122

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 55,494 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000056 · wf-form4_158777422299168.xml · nonDerivative · entry 2

SCANGOS GEORGE A · CIK 0001202102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 753,031

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.04 to $26.47. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-20-000056 · wf-form4_158777422299168.xml · nonDerivative · entry 1

SCANGOS GEORGE A · CIK 0001202102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 808,731

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.04 to $26.03. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

SEC source: 0000939767-20-000055 · wf-form4_158777414013343.xml · derivative · entry 5

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 5,000 shares

Expires 2021-09-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option, representing the right to purchase a total of 120,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.

SEC source: 0000939767-20-000055 · wf-form4_158777414013343.xml · nonDerivative · entry 2

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,873

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019.

SEC source: 0000939767-20-000055 · wf-form4_158777414013343.xml · nonDerivative · entry 1

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,873

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 72,614 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000053 · wf-form4_158760303289913.xml · nonDerivative · entry 5

SCANGOS GEORGE A · CIK 0001202102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 853,031

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019.

F6 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.15. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 6 to this Form 4.

SEC source: 0000939767-20-000054 · wf-form4_158760679716513.xml · nonDerivative · entry 8

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 426,322

F6 · kind: On April 22, 2020, the Reporting Person gifted 87,079 shares to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended

SEC source: 0000939767-20-000054 · wf-form4_158760679716513.xml · nonDerivative · entry 7

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,784

F6 · kind: On April 22, 2020, the Reporting Person gifted 87,079 shares to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended

SEC source: 0000939767-20-000053 · wf-form4_158760303289913.xml · nonDerivative · entry 4

SCANGOS GEORGE A · CIK 0001202102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 857,231

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019.

F5 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.01 to $25.10. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 5 to this Form 4.

SEC source: 0000939767-20-000054 · wf-form4_158760679716513.xml · derivative · entry 11

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 220,000 shares

Expires 2020-09-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The option, representing the right to purchase a total of 720,000 shares of Common Stock, became fully exercisable on September 18, 2017.

SEC source: 0000939767-20-000054 · wf-form4_158760679716513.xml · nonDerivative · entry 6

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 253,863

F5 · kind: Represents a "net exercise" of an outstanding stock option. The Reporting Person received 80,799 shares of Common Stock on the net exercise of a stock option to purchase 220,000 shares of Common Stock. The Issuer withheld 139,201 shares of Common Stock underlying the stock option for payment of the exercise price and tax withholding using a stock price on April 21, 2020 of $24.56.

SEC source: 0000939767-20-000054 · wf-form4_158760679716513.xml · nonDerivative · entry 5

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 393,064

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-20-000053 · wf-form4_158760303289913.xml · nonDerivative · entry 3

SCANGOS GEORGE A · CIK 0001202102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 863,031

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019.

F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.59 to $24.88. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4.

SEC source: 0000939767-20-000053 · wf-form4_158760303289913.xml · nonDerivative · entry 2

SCANGOS GEORGE A · CIK 0001202102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 868,931

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.59 to $24.58. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-20-000053 · wf-form4_158760303289913.xml · nonDerivative · entry 1

SCANGOS GEORGE A · CIK 0001202102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 894,531

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.59 to $23.58. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

SEC source: 0000939767-20-000054 · wf-form4_158760679716513.xml · derivative · entry 10

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 240,000 shares

Expires 2020-09-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: On September 18, 2013, the Reporting Person was granted a performance-based stock option to purchase 480,000 shares of Common Stock under the Exelixis, Inc. 2011 Equity Incentive Plan. Vesting of the option is tied to performance goals set by the Compensation Committee ("Committee") as follows: (i) 50% of the option will vest if the Committee determines that top-line efficacy data received from the METEOR Phase 3 clinical trial of cabozantinib in metastatic renal cell carcinoma met its primary endpoint at a specified level, which the Committee determined had been achieved on July 20, 2015, resulting in the vesting of 50% of the option; and (ii) 50% of the option will vest if the Committee confirms the approval of cabozantinib by the U.S. Food and Drug Administration or European Medicines Agency for the treatment of metastatic castration-resistant prostate cancer, which the Committee determined could not be achieved on December 10, 2014, resulting in the forfeiture of 50% of the option.

SEC source: 0000939767-20-000054 · wf-form4_158760679716513.xml · nonDerivative · entry 4

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 173,064

F4 · kind: Represents a "net exercise" of an outstanding stock option. The Reporting Person received 87,079 shares of Common Stock on the net exercise of a stock option to purchase 240,000 shares of Common Stock. The Issuer withheld 152,921 shares of Common Stock underlying the stock option for payment of the exercise price and tax withholding using a stock price on April 20, 2020 of $23.58.

SEC source: 0000939767-20-000054 · wf-form4_158760679716513.xml · nonDerivative · entry 2

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 325,985

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · balance_after: Includes 85,985 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000052 · wf-form4_158760292542905.xml · derivative · entry 5

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 5,000 shares

Expires 2021-09-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option, representing the right to purchase a total of 120,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.

SEC source: 0000939767-20-000052 · wf-form4_158760292542905.xml · nonDerivative · entry 2

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,873

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019.

SEC source: 0000939767-20-000052 · wf-form4_158760292542905.xml · nonDerivative · entry 1

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,873

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 72,614 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000049 · wf-form4_158716867487658.xml · nonDerivative · entry 1

SCANGOS GEORGE A · CIK 0001202102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 913,031

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person o November 26, 2019.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.11 to $18.56. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

SEC source: 0000939767-20-000048 · wf-form4_158647799860062.xml · nonDerivative · entry 2

SCANGOS GEORGE A · CIK 0001202102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 938,031

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.03 to $18.59. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-20-000048 · wf-form4_158647799860062.xml · nonDerivative · entry 1

SCANGOS GEORGE A · CIK 0001202102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 945,096

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.56. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

SEC source: 0000939767-20-000047 · wf-form4_158639115453049.xml · derivative · entry 4

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,000

Underlying: Common Stock · 50,000 shares

Expires 2020-09-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing the right to purchase a total of 126,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 18, 2017.

SEC source: 0000939767-20-000047 · wf-form4_158639115453049.xml · nonDerivative · entry 2

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,531

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2020.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.76 to $17.66. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-20-000047 · wf-form4_158639115453049.xml · nonDerivative · entry 1

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 176,531

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 44,057 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000046 · wf-form4_158596070667563.xml · derivative · entry 5

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2020-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing the right to purchase a total of 30,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 23, 2013.

SEC source: 0000939767-20-000046 · wf-form4_158596070667563.xml · derivative · entry 4

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2020-05-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 19, 2010.

SEC source: 0000939767-20-000046 · wf-form4_158596070667563.xml · nonDerivative · entry 3

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,678

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.34 to $16.80. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-20-000046 · wf-form4_158596070667563.xml · nonDerivative · entry 2

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,526

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-20-000046 · wf-form4_158596070667563.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,526

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 10,317 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000045 · wf-form4_158587246981282.xml · nonDerivative · entry 1

SCANGOS GEORGE A · CIK 0001202102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 961,531

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.14. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

SEC source: 0000939767-20-000044 · wf-form4_158475260117342.xml · nonDerivative · entry 1

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,873

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.06 to $15.74. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

F3 · balance_after: Includes 72,614 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000054 · wf-form4_158760679716513.xml · nonDerivative · entry 3

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 339,243

F1 · kind: On March 9, 2020, the Reporting Person gifted 17,116 shares to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended

F3 · ownership.nature: Shares held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended.

SEC source: 0000939767-20-000054 · wf-form4_158760679716513.xml · nonDerivative · entry 1

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,985

F1 · kind: On March 9, 2020, the Reporting Person gifted 17,116 shares to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended

SEC source: 0000939767-20-000043 · wf-form4_158354323258777.xml · derivative · entry 5

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 470,000

Underlying: Common Stock · 50,000 shares

Expires 2020-09-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing the right to purchase a total of 720,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 18, 2017.

SEC source: 0000939767-20-000043 · wf-form4_158354323258777.xml · nonDerivative · entry 2

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,101

F2 · kind: Represents a "net exercise" of an outstanding stock option. The Reporting Person received 17,116 shares of Common Stock on the net exercise of a stock option to purchase 50,000 shares of Common Stock. The Issuer withheld 32,884 shares of Common Stock underlying the stock option for payment of the exercise price and tax withholding using a stock price on March 4, 2020 of $19.89.

SEC source: 0000939767-20-000043 · wf-form4_158354323258777.xml · nonDerivative · entry 1

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,985

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 85,985 shares of Exelixis, Inc. Common Stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000042 · wf-form4_158354287693678.xml · derivative · entry 5

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 100,000 shares

Expires 2021-09-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option, representing the right to purchase a total of 500,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.

SEC source: 0000939767-20-000042 · wf-form4_158354287693678.xml · nonDerivative · entry 3

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 325,122

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.60 to $19.62. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

SEC source: 0000939767-20-000042 · wf-form4_158354287693678.xml · nonDerivative · entry 2

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 375,122

SEC source: 0000939767-20-000042 · wf-form4_158354287693678.xml · nonDerivative · entry 1

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 425,122

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 55,494 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-20-000041 · wf-form4_158345642118424.xml · derivative · entry 6

FELDBAUM CARL B · CIK 0001326377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires 2020-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option, representing the right to purchase a total of 30,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 23, 2013.